Treatment with SGLT-2 inhibitors can diminish the risk of cancer incidence in DM patients [138] because gliflozins have anticancer activity through various mechanisms, as previously shown [139,140,141,142,143,144,145]. This evidence concerns the gene SLC5A2 and diabetes mellitus.